Drug discovery and development: introduction to the general public and patient groups

Natesh Singh, P. Vayer, Shivalika Tanwar, J. Poyet, K. Tsaioun, B. Villoutreix
{"title":"Drug discovery and development: introduction to the general public and patient groups","authors":"Natesh Singh, P. Vayer, Shivalika Tanwar, J. Poyet, K. Tsaioun, B. Villoutreix","doi":"10.3389/fddsv.2023.1201419","DOIUrl":null,"url":null,"abstract":"Finding new drugs usually consists of five main stages: 1) a pre-discovery stage in which basic research is performed to try to understand the mechanisms leading to diseases and propose possible targets (e.g., proteins); 2) the drug discovery stage, during which scientists search for molecules (two main large families, small molecules and biologics) or other therapeutic strategies that interfere or cure the investigated disease or at least alleviate the symptoms; 3) the preclinical development stage that focuses on clarifying the mode of action of the drug candidates, investigates potential toxicity, validates efficacy on various in vitro and in vivo models, and starts evaluate formulation; 4) the clinical stage that investigates the drug candidate in humans; 5) the reviewing, approval and post-market monitoring stage during which the drug is approved or not. In practice, finding new treatments is very challenging. Despite advances in the understanding of biological systems and the development of cutting-edge technologies, the process is still long, costly with a high attrition rate. New approaches, such as artificial intelligence and novel in vitro technologies, are being used in an attempt to rationalize R&D and bring new drugs to patients faster, but several obstacles remain. Our hope is that one day, it becomes possible to rapidly design inexpensive, more specific, more effective, non-toxic, and personalized drugs. This is a goal towards which all authors of this article have devoted most of their careers. Graphical Abstract","PeriodicalId":73080,"journal":{"name":"Frontiers in drug discovery","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fddsv.2023.1201419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Finding new drugs usually consists of five main stages: 1) a pre-discovery stage in which basic research is performed to try to understand the mechanisms leading to diseases and propose possible targets (e.g., proteins); 2) the drug discovery stage, during which scientists search for molecules (two main large families, small molecules and biologics) or other therapeutic strategies that interfere or cure the investigated disease or at least alleviate the symptoms; 3) the preclinical development stage that focuses on clarifying the mode of action of the drug candidates, investigates potential toxicity, validates efficacy on various in vitro and in vivo models, and starts evaluate formulation; 4) the clinical stage that investigates the drug candidate in humans; 5) the reviewing, approval and post-market monitoring stage during which the drug is approved or not. In practice, finding new treatments is very challenging. Despite advances in the understanding of biological systems and the development of cutting-edge technologies, the process is still long, costly with a high attrition rate. New approaches, such as artificial intelligence and novel in vitro technologies, are being used in an attempt to rationalize R&D and bring new drugs to patients faster, but several obstacles remain. Our hope is that one day, it becomes possible to rapidly design inexpensive, more specific, more effective, non-toxic, and personalized drugs. This is a goal towards which all authors of this article have devoted most of their careers. Graphical Abstract
药物发现和开发:向公众和患者群体介绍
发现新药通常包括五个主要阶段:1)发现前阶段,进行基础研究,试图了解导致疾病的机制并提出可能的靶点(如蛋白质);2) 药物发现阶段,在此期间,科学家寻找干扰或治愈所研究疾病或至少缓解症状的分子(两个主要的大家族,小分子和生物制品)或其他治疗策略;3) 临床前开发阶段,重点是阐明候选药物的作用模式,调查潜在毒性,验证各种体外和体内模型的疗效,并开始评估配方;4) 在人体中研究候选药物的临床阶段;5) 药品是否获得批准的审查、批准和上市后监测阶段。在实践中,寻找新的治疗方法是非常具有挑战性的。尽管对生物系统的理解和尖端技术的发展取得了进展,但这一过程仍然漫长、昂贵且损耗率高。人工智能和新型体外技术等新方法正在被用于使研发合理化,并更快地将新药带给患者,但仍存在一些障碍。我们希望有一天,能够快速设计出廉价、更特异、更有效、无毒、个性化的药物。这是本文所有作者在职业生涯的大部分时间里都致力于实现的目标。图形摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信